Matthew Beyersdorf assists the Biotechnology Practice in patent drafting, patent prosecution, due diligence support, IP portfolio management, and freedom-to-operate searching in the areas of molecular biology, gene editing, cellular biology, drug development, and genetics. He has extensive knowledge in the areas of cell biology, protein biochemistry, drug discovery, chemistry of natural products, and transcriptional mechanisms of metastatic cancer.
Prior to joining Wolf Greenfield, Matthew earned a doctorate in Chemical Biology at the University of Michigan, where his thesis research centered on the discovery of natural products and organic small molecules that modulate transcriptional protein-protein interactions involved in cancer progression. During this time, he was involved in high-throughput screening efforts of a natural products library, developed NMR methods for studying protein-protein interactions, utilized process chemistry approaches to produce large-scale quantities of microbial secondary metabolites, proteins and synthetic peptides, and studied the effects of organic small molecules in human cancer cells using cellular reporter assays.
Additionally, Matthew was a Project Manager and the Director of Public Relations at miLEAD Consulting Group, a non-profit consulting firm that provides short-term services to scientists and technology companies in Southeast Michigan.
- Assisted in preparation and prosecution of patent applications in the areas of antibody therapeutics, CAR-T therapy, methods of genome editing, nucleic acid therapeutics, and nucleic acid structural motifs
- Conducted several freedom-to-operate studies for an industrial client in advance of filing Investigational New Drug applications
- Assisted in conducting a broad evaluation of a company’s IP portfolio in order to assist with re-structuring their ongoing IP strategy
- Assisted in the development and early implementation of an IP strategy for a start-up biological therapeutics company
- Conducted due diligence studies on patent landscape and market exclusivity in connection with anticipated biotechnology acquisition
- American Chemical Society
- US Dept. of Education GAANN Fellow, University of Michigan
- Joy ST, Henley MJ, De Salle SN, Beyersdorf MS, Vock IW, Huldin AJL, Mapp AK. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb. J Am Chem Soc. 2021 Sep 22;143(37):15056-15062.
- Henderson AR, Henley MJ, Foster NJ, Peiffer AL, Beyersdorf MS, Stanford KD, Sturlis SM, Linhares BM, Hill ZB, Wells JA, Cierpicki T, Brooks CL 3rd, Fierke CA, Mapp AK. Conservation of coactivator engagement mechanism enables small-molecule allosteric modulators. Proc Natl Acad Sci U S A. 2018;115(36):8960-8965.
- Lookadoo DB, Beyersdorf MS, Halkides CJ. Synthesis of a Stable Analog of the Phosphorylated Form of CheY: Phosphono-CheY. Methods in Molecular Biology 2018;1729:337-343.
- Beyersdorf MS, Sircar R, Lookadoo DB, Bottone CJ, Lynch MJ, Crane BR, Halkides CJ. Production, characterization, and assessment of a stable analog of the response regulator CheY-phosphate from Thermotoga maritima. Protein Science. 2017 Aug;26(8):1547-1554.
- Sircar R, Borbat PP, Lynch MJ, Bhatnagar J, Beyersdorf MS, Halkides CJ, Freed JH, Crane BR. Assembly states of FliM and FliG within the flagellar switch complex. J. Molecular Biology 2015 Feb 27;427(4):867-86.
Matt enjoys exploring parks and playing soccer with his young son, cooking lavish meals to relax, and watching the latest prestige television show.